Saturday, April 01, 2023
Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, today announced that Health Canada has approved FERRIPROX MR deferiprone extended-release tablets 1 000 mg for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate, or sickle cell disease (SCD) or other anemias.
FERRIPROX (deferiprone) was previously approved in Canada for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate in 2015, and subsequently approved for the treatment of iron overload in patients with SCD or other anemias in 2021.
"As a family business and a B Corp focused on the long-term support of rare disease communities, we have the opportunity to remain close to the patients, caregivers and their providers, always learning from them and responding to their needs," said Giacomo Chiesi, head of Chiesi Global Rare Diseases. "That is why we found it important to pursue the development of a twice-a-day tablet formulation of FERRIPROX, which reflects our ongoing commitment to patients with transfusional iron overload."
Thalassemia syndromes and SCD are disorders that affect red blood cells. Both conditions cause problems with hemoglobin, depriving many parts of the body of oxygen. People living with these conditions often require chronic blood transfusions that can put them at risk of developing very high levels of iron in their blood and vital organs. FERRIPROX is a synthetic, orally active iron-chelating agent shown to be effective in reducing iron concentration by penetrating cell membranes and removing toxic iron from organ tissues and extracellular fluids.